SOHO Brazil

 

SOHO Brazil 2024
Avatar

Where I Use Azacitidine and Venetoclax in AML: Present and Future

By SOHO Brazil 2024 FEATURING Jeffrey Lancet
By SOHO Brazil 2024 FEATURING Jeffrey Lancet
375 views
July 11, 2024
0 Comments
Login to view comments. Click here to Login

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison
SOHO Brazil 2024
18:13
SOHO Brazil 2024

SOHO Brazil 2024: Treatment of Primary CNS Lymphoma

Feat. A. Alencar
20:49
SOHO Brazil 2024

Summary of Recent Updates in Advanced Hodgkin Lymphoma

Feat. C. Moskowitz
27:26
SOHO Brazil 2024

Where I Use Azacitidine and Venetoclax in AML: Present and Future

Feat. J. Lancet
22:29
SOHO Brazil 2024

1L Therapy in CLL: What Are the Best Options?

Feat. J. Burger
13:22
SOHO Brazil 2024

Managing Infectious Complications With Bispecific and CAR-T Therapy …

Feat. N. S. Raje
20:23
SOHO Brazil 2024

When to Consider Bispecific and CAR-T Therapy in MM

Feat. N. S. Raje
16:44
SOHO Brazil 2024

Frontline MM: Are Four Better Than Three?

Feat. N. S. Raje
19:14
SOHO Brazil 2024

FL: How Do I Deal With Relapse?

Feat. B. Kahl
15:25
SOHO Brazil 2024

To 2L and Beyond: Treatment Options in R/R MCL

Feat. T. Phillips
20:01
SOHO Brazil 2024

FL Updates: Is There a Standard 1L Treatment?

Feat. B. Kahl
21:12
SOHO Brazil 2024

3L in CLL: The Best Options in a Patient Double-Refractory to Covale…

Feat. J. Burger
18:29
SOHO Brazil 2024

Single vs. Multiple Agents in 2L Therapy for CLL

Feat. J. Burger
19:21
SOHO Brazil 2024

Understanding the NPM1 Mutation in AML: Dr. Jekyll and Mr. Hyde

Feat. J. Lancet
17:01
SOHO Brazil 2024

Are We Closer to Conquering HR-MDS?

Feat. R. Komrokji
21:26
SOHO Brazil 2024

Therapies on the Horizon in LR- and HR-MDS

Feat. R. Komrokji
20:25
SOHO Brazil 2024

What Is the Best Timing for Bispecific Antibodies and CAR-T Therapy …

Feat. A. Zelenetz
14:17
SOHO Brazil 2024

DLBCL Pts Ineligible for CAR-T Therapy: Do They Exist and How Do We …

Feat. A. Zelenetz
15:02
SOHO Brazil 2024

Summary of Updates in R/R DLBCL Treatment

Feat. A. Alencar
22:11
SOHO Brazil 2024

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

Feat. A. Zelenetz
18:06
SOHO Brazil 2024

Summary of Recent Updates in R/R HL

Feat. C. Moskowitz
19:13
SOHO Brazil 2024

Summary of Recent Updates on LR-MDS Management

Feat. R. Komrokji
19:52
SOHO Brazil 2024

How Are Targeted Therapies Redefining the Treatment Paradigm in ALL …

Feat. J. Burger
19:07
SOHO Brazil 2024

Early Stage HL: Can Radiation Therapy Be Eliminated?

Feat. C. Moskowitz
38:54
SOHO Brazil 2024

PNH: Summary of Latest Advancements and Case Discussion

Feat. B. Fattizzo
20:33
SOHO Brazil 2024

The Gold Standard in the Use of FLT3 and IDH Inhibitors in AML

Feat. J. Lancet
17:30
SOHO Brazil 2024

Making Sense of 1L Treatment Options in MCL

Feat. T. Phillips